OneMedNet Stock Soars 28.9% on Massive Share Offering and AI Partnerships

Introduction

ONEMEDNET CORP (NASDAQ: ONMD, 원메드넷) is a data technology company headquartered in Eden Prairie, Minnesota. Through its iRWD™ platform, the firm provides regulatory-grade, de-identified real-world data (RWD) to healthcare, finance, retail, and telecom customers. As of November 27, 2025, ONMD shares traded at $1.83, reflecting an increase of 28.87% on a volume of 974,671.

Corporate Structure and Operations

Founded in 2009, OneMedNet curates clinical imaging and longitudinal patient records from more than 2,130 provider sites across the United States. Its subscription-based iRWD™ service delivers:

• Complete patient records, including clinical exams and administrative claims
• Real-time cohort updates over years of longitudinal data
• AI-driven data masking with human-in-the-loop quality assurance

OneMedNet's network includes 47 million de-identified patient records and 186 million clinical exams and images. Headcount details are not publicly disclosed.

Real-world data by Luke Chesser

Developments and News

• On November 14, 2025, OneMedNet filed its Form 10-Q for the quarter ended September 30, 2025, and a prospectus supplement (Rule 424(b)(3)) registering up to 11.5 million primary shares and 28.15 million secondary shares.
• In November 2025, the company reported adding 380 provider sites since August 2025, representing a 22% increase and expanding its de-identified record set by 38%.
• In October 2025, OneMedNet announced strategic alliances with mlHealth360 for healthcare AI analytics and with Palantir Technologies to enhance its RWD analytics infrastructure.

Financial and Strategic Analysis

For Q3 2025 (ended September 30, 2025), OneMedNet reported:

• Revenue of $177,000 (decreased 37% year-over-year, increased 14% sequentially)
• Net loss of $741,000 (compared to $440,000 in Q2 2025)
• Basic and diluted EPS of –$0.01 (compared to –$0.36 in Q3 2024)

On a trailing-twelve-month basis, revenue was reported at $643,000 with a net loss of $10.13 million. As of November 27, 2025, key market metrics included a market capitalization of $93.34 million, 51.01 million shares outstanding, a P/E ratio of 22.2 (based on a negative TTM EPS), and a debt-to-equity ratio of 27.35%.

Strategically, OneMedNet is utilizing its prospectus-registered offerings to support network growth, platform enhancements, and potential acquisitions. Its subscription model and proprietary data-masking technology address demand for compliant, AI-ready datasets in life sciences and other industries.

Market Position and Industry Context

OneMedNet operates in the global RWD market, competing with established players in healthcare analytics and software. The company's focus on real-time, longitudinal clinical and imaging data differentiates it from providers of static datasets. The stock trades within its 52-week range ($0.30–$4.22) and above its 200-day moving average. With a beta of 1.14, ONMD’s share price shows moderate sensitivity to broader market movements. The demand for regulatory-grade RWD and AI-ready platforms is increasing due to growing post-market surveillance requirements and AI adoption in life sciences.

tl;dr

On November 14, 2025, OneMedNet reported Q3 2025 results showing $177,000 in revenue and a net loss of $741,000, while filing a prospectus to raise up to 39.65 million shares. In mid-November, its provider network reached 2,130 sites with 47 million de-identified records. The stock increased by 28.87% to $1.83 on November 27 amid increased trading volume. Ongoing share offerings and partnerships with mlHealth360 and Palantir reflect its efforts to expand its AI-ready real-world data platform.